25817898 31196659 22956414 29172824 21949629 20859542 20965951 27110365 26363473 21846157 24496517 21640714 22051431 20963497 26987022 22020885 20929253 22513185 25624753 28885265 - Search Results

Year	Number of Results
2010	4
2011	5
2012	2
2014	1
2015	4
2016	2
2017	1
2018	2
2019	1
2020	1
2022	0

1

Steap4 attenuates high glucose and S100B-induced effects in mesangial cells.

Chuang CT, Guh JY, Lu CY, Wang YT, Chen HC, Chuang LY. Chuang CT, et al. J Cell Mol Med. 2015 Jun;19(6):1234-44. doi: 10.1111/jcmm.12472. Epub 2015 Mar 27. J Cell Mol Med. 2015. PMID: 25817898 Free PMC article.

2

Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?

Caravaca-Fontán F, Valladares J, Díaz-Campillejo R, Barroso S, Luna E, Caravaca F. Caravaca-Fontán F, et al. Nefrologia (Engl Ed). 2020 Jan-Feb;40(1):38-45. doi: 10.1016/j.nefro.2019.02.013. Epub 2019 Jun 10. Nefrologia (Engl Ed). 2020. PMID: 31196659 Free article. English, Spanish.

3

Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease.

Chen K, Keaney JF Jr. Chen K, et al. Curr Atheroscler Rep. 2012 Oct;14(5):476-83. doi: 10.1007/s11883-012-0266-8. Curr Atheroscler Rep. 2012. PMID: 22956414 Free PMC article. Review.

4

Aliskiren and valsartan in combination is a promising therapy for hypertensive renal injury in rats.

Abdel Kawy HS. Abdel Kawy HS. Clin Exp Hypertens. 2018;40(6):560-568. doi: 10.1080/10641963.2017.1407333. Epub 2017 Nov 27. Clin Exp Hypertens. 2018. PMID: 29172824

5

Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control.

Rashid HU. Rashid HU. Integr Blood Press Control. 2010;3:133-44. doi: 10.2147/IBPC.S12407. Epub 2010 Oct 5. Integr Blood Press Control. 2010. PMID: 21949629 Free PMC article.

6

Aliskiren and valsartan combination therapy for the management of hypertension.

Epstein BJ. Epstein BJ. Vasc Health Risk Manag. 2010 Sep 7;6:711-22. doi: 10.2147/vhrm.s8175. Vasc Health Risk Manag. 2010. PMID: 20859542 Free PMC article. Review.

7

Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.

Gullapalli N, Bloch MJ, Basile J. Gullapalli N, et al. Ther Adv Cardiovasc Dis. 2010 Dec;4(6):359-73. doi: 10.1177/1753944710384430. Epub 2010 Oct 21. Ther Adv Cardiovasc Dis. 2010. PMID: 20965951 Free article. Review.

8

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012.

Wu B, Bell K, Stanford A, Kern DM, Tunceli O, Vupputuri S, Kalsekar I, Willey V. Wu B, et al. BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000154. doi: 10.1136/bmjdrc-2015-000154. eCollection 2016. BMJ Open Diabetes Res Care. 2016. PMID: 27110365 Free PMC article.

9

Oxidative stress in chronic vascular disease: From prediction to prevention.

Santilli F, D'Ardes D, Davì G. Santilli F, et al. Vascul Pharmacol. 2015 Nov;74:23-37. doi: 10.1016/j.vph.2015.09.003. Epub 2015 Sep 10. Vascul Pharmacol. 2015. PMID: 26363473 Review.

10

The role of direct renin inhibition in clinical practice: focus on combination therapy.

Rashid HU, Mende C. Rashid HU, et al. Am J Cardiovasc Drugs. 2011 Oct 1;11(5):303-15. doi: 10.2165/11594140-000000000-00000. Am J Cardiovasc Drugs. 2011. PMID: 21846157 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results